Patterns of response to anti-CGRP monoclonal antibodies during first 6-months of treatment in resistant migraine patients: impact on outcome.

Abstract

The response pattern to monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAbs) shown in migraine prevention clinical trials is not always reproducible at an individual-level. To describe patterns of start and consistency of the response to anti-CGRP MAbs during first six months of treatment and the association to baseline clinical characteristics METHODS: This is a prospective clinical cohort observational study. We included migraine patients treated with erenumab or galcanezumab evaluated at baseline and after three and six months (M3-M6) of treatment. The response was categorized according to reduction in monthly headache days (MHD): Sustained-response (SustainedR, ≥50% at M3 and M6); Short-Response (ShortR, M3≥50% and M6<50%), Later-Response (LaterR, M3<50% and M6≥50%); Limited-Response (LimitedR, 25-50% at M3 and M6) and No-Response (NoR, <25% at M3 and M6). Response patterns were compared at baseline and with outcome variables at M3 and M6. We included 357 patients with a headache frequency of 21.0(16.0, 28.0) MHD and 84.0% (300/357) were chronic migraine. The distribution according to response pattern was: 37.0% (110/297) Sustained-Response, 16.8% (50/297) Later-Response, 10.4% (31/297) Short-Response, 22.6% (67/297) Limited-Response and 13.1% showed No-Response (39/297). Sustained-R and Later-R groups showed statistically significant anxiety and depression score reduction at M3 and M6 compared to other groups. Initial response to anti-CGRP MAbs is not consistent in all patients. Persistence of anxiety and depression might be associated with lower response rates at month 6.